Search

Your search keyword '"Florin Andrei"' showing total 354 results

Search Constraints

Start Over You searched for: Author "Florin Andrei" Remove constraint Author: "Florin Andrei" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
354 results on '"Florin Andrei"'

Search Results

1. Evaluation of the Immunohistochemical Scoring System of CDX2 Expression as a Prognostic Biomarker in Colon Cancer

2. Impact of Structural Strain in Perovskite Epitaxial Thin Films on Their Functional Properties

3. SAF-T – The Reporting that Will Improve the Collection?

4. Clinicopathological correlations of neuroendocrine cell hyperplasia in ulcerative colitis patients

5. Histological scoring systems in ulcerative colitis patients: a routine practice perspective

6. Multispectral Data Analysis for Semantic Assessment—A SNAP Framework for Sentinel-2 Use Case Scenarios

7. Nitrites Detection with Sensors Processed via Matrix-Assisted Pulsed Laser Evaporation

8. Kaolinite Thin Films Grown by Pulsed Laser Deposition and Matrix Assisted Pulsed Laser Evaporation

9. Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer

11. Thickness-Dependent Photoelectrochemical Water Splitting Properties of Self-Assembled Nanostructured LaFeO3 Perovskite Thin Films

13. The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype

14. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer

15. The Influence of the Structural and Morphological Properties of WO3 Thin Films Obtained by PLD on the Photoelectrochemical Water-Splitting Reaction Efficiency

19. Return of individual genomic research results within the PRAEGNANT multicenter registry study

20. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry

21. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

22. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

23. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers.

24. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

25. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study

26. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

28. Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast Cancer.

29. Screening and evaluation of potential recipients and donors for living donor uterus transplantation: results from a single-center observational study

30. TERT promoter mutation in adult granulosa cell tumor of the ovary

31. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

32. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry

33. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

34. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

35. Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register

36. Evaluation of the Immunohistochemical Scoring System of CDX2 Expression as a Prognostic Biomarker in Colon Cancer.

39. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs.

40. Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020.

42. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

43. Corrigendum to 'Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany'

48. Electrochemotherapy – supplementary treatment for loco-regional metastasized breast carcinoma administered to concomitant systemic therapy

50. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT

Catalog

Books, media, physical & digital resources